Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12513991 | 0.94 | KCNH2 (0.51) | KCNH2BACE1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL12437741 | 0.88 | UTS2R (0.47) | LMNAALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL12437739 | 0.88 | BCHE (0.53) | LMNAALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL12513887 | 0.88 | ALDH1A1 (0.48) | KCNH2BACE1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL12437738 | 0.87 | UTS2R (0.52) | MAPTTP53DRD2UTS2R | |
| SCHEMBL12437702 | 0.84 | MEN1 (0.47) | MAPTTP53DRD2UTS2R | |
| SCHEMBL12437723 | 0.84 | MAPT (0.51) | ALDH1A1KDM4EMAPTTP53UTS2R | |
| SCHEMBL12437827 | 0.84 | CACNA1G (0.49) | ALDH1A1KDM4EMAPTUTS2R | |
| SCHEMBL12437875 | 0.84 | UTS2R (0.45) | LMNAALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL12437857 | 0.84 | TP53 (0.45) | LMNAALDH1A1SMN1; SMN2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | KCNH2 4831/4885BACE1 3038/4885LMNA 2809/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | KCNH2 4831/4885BACE1 3038/4885LMNA 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.